Shares of Panacea Biotec gained 10.9 percent intraday on December 19 after the company bagged an order for supplying Pentavalent vaccine from UN agencies.
The stock also rallied 11 percent in previous session. It was quoting at Rs 132.70, up Rs 7.45, or 5.95 percent amid high volumes on the BSE at 1052 hours IST.
Panacea Biotec said it had received awards worth $24.32 million (over Rs 170 crore) from UN Agencies (UNICEF and PAHO).
The contract is for the supply of its Easyfive-TT, a fully liquid WHO prequalified wP based Pentavalent vaccine (DTwP-HepB-Hib), it added.
"UNICEF award is for the calendar year 2020 and award of PAHO is for three calendar years i.e. 2020-2022," company said in its BSE filing.
Pediatric vaccination plays an important role to achieve Sustainable Development Goals set by the United Nations, in particular, the target to reduce the under-five mortality rate to less than 25 per 1,000 live births.
Pentavalent vaccine protects children against five deadly diseases; Diphtheria, Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b - becoming the foundation of paediatric immunization programs across the world.
Easyfive-TT was introduced by Panacea Biotec as world's first fully liquid wP-based pentavalent vaccine in the Indian market in year 2005. With WHO prequalification in 2008, over 100 million doses have been supplied to more than 50 countries globally.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
